The pandemic reshapes treatment intervals for neovascular AMD, revealing flexible strategies that maintain visual outcomes and enhance patient care.
Loredana Smarandache, MD
Advertisement
Articles by Loredana Smarandache, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Modern Retina
1
Ocugen completes dosing early in phase 2/3 GARDian3 trial for Stargardt disease
2
OLN324 shows comparable vision gains, potential durability advantage vs faricimab in phase 1b wAMD, DME study
3
Tattoo-associated uveitis: An emerging eye health challenge
4
FDA grants RMAT designation to RTx-015 optogenetic gene therapy for retinitis pigmentosa
5